跳至主要内容
临床试验/NCT00380276
NCT00380276终止3 期

Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type

Myrexis Inc.0 个研究点目标入组 1,000 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
Myrexis Inc.
入组人数
1,000
主要终点
Primary Safety

研究概览

简要总结

Open-label treatment with MPC-7869 for participants in a previous randomized study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
55 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participation in a previous MPC-7869 randomized protocol
  • Have had a diagnosis of probable Alzheimer's disease.
  • Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
  • Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
  • Female subjects must be surgically sterile or postmenopausal for > 1 year.
  • Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.

排除标准

  • History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
  • Chronic or acute renal, hepatic or metabolic disorder.
  • Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.

研究组 & 干预措施

Open Label Arm

Other

Treatment is open-label

干预措施: MPC-7869 (Drug)

结局指标

主要结局

Primary Safety

时间窗: For study duration

次要结局

未报告次要终点

研究者

发起方
Myrexis Inc.
申办方类型
Industry

相似试验